Literature DB >> 26664352

Pulmonary Overlap Syndromes, with a focus on COPD and ILD.

Katherine A Dudley, Atul Malhotra, Robert L Owens.   

Abstract

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Obstructive sleep apnea; Overlap Syndrome; Sleep

Year:  2014        PMID： 26664352      PMCID： PMC4671775          DOI： 10.1016/j.jsmc.2014.05.008

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN： 1556-407X


× No keyword cloud information.
  127 in total

Review 1.  The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies.

Authors:  Magali Poulain; Mariève Doucet; Geneviève C Major; Vicky Drapeau; Frédéric Sériès; Louis-Philippe Boulet; Angelo Tremblay; François Maltais
Journal:  CMAJ       Date:  2006-04-25       Impact factor: 8.262

2.  Reflex effects of upper airway irritation on total lung resistance and blood pressure.

Authors:  J A NADEL; J G WIDDICOMBE
Journal:  J Appl Physiol       Date:  1962-11       Impact factor: 3.531

3.  Exercise hemodynamics and gas exchange in patients with chronic obstruction pulmonary disease, sleep desaturation, and a daytime PaO2 above 60 mm Hg.

Authors:  E C Fletcher; R A Luckett; T Miller; J G Fletcher
Journal:  Am Rev Respir Dis       Date:  1989-11

Review 4.  Night-time symptoms: a forgotten dimension of COPD.

Authors:  A Agusti; J Hedner; J M Marin; F Barbé; M Cazzola; S Rennard
Journal:  Eur Respir Rev       Date:  2011-09-01

5.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

6.  Thoracic influence on upper airway patency.

Authors:  W B Van de Graaff
Journal:  J Appl Physiol (1985)       Date:  1988-11

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

8.  Cognitive impairment in patients with obstructive sleep apnea and associated hypoxemia.

Authors:  L J Findley; J T Barth; D C Powers; S C Wilhoit; D G Boyd; P M Suratt
Journal:  Chest       Date:  1986-11       Impact factor: 9.410

9.  Effect of triazolam on sleep and arterial oxygen saturation in patients with chronic obstructive pulmonary disease.

Authors:  R M Timms; A Dawson; R M Hajdukovic; M M Mitler
Journal:  Arch Intern Med       Date:  1988-10

10.  Evaluation of left ventricular function in chronic pulmonary disease by exercise gated equilibrium radionuclide angiography.

Authors:  R Slutsky; W Hooper; W Ackerman; W Ashburn; K Gerber; K Moser; J Karliner
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749
View more
  4 in total

1.  Intermittent Hypoxia Contributes to the Lung Damage by Increased Oxidative Stress, Inflammation, and Disbalance in Protease/Antiprotease System.

Authors:  I Tuleta; F Stöckigt; U R Juergens; C Pizarro; J W Schrickel; G Kristiansen; G Nickenig; D Skowasch
Journal:  Lung       Date:  2016-10-13       Impact factor: 2.584

2.  Noninvasive auto-titrating ventilation (AVAPS-AE) versus average volume-assured pressure support (AVAPS) ventilation in hypercapnic respiratory failure patients.

Authors:  Gul Gursel; Avsar Zerman; Burcu Basarik; Kamil Gonderen; Muge Aydogdu; Serriyye Memmedova
Journal:  Intern Emerg Med       Date:  2018-03-06       Impact factor: 3.397

Review 3.  Sleep in Chronic Obstructive Pulmonary Disease: Evidence Gaps and Challenges.

Authors:  Rachel Jen; Yanru Li; Robert L Owens; Atul Malhotra
Journal:  Can Respir J       Date:  2016-06-08       Impact factor: 2.409

4.  Risk of atrial fibrillation in patients with pneumoconiosis: A nationwide study in Taiwan.

Authors:  Wei-Syun Hu; Cheng-Li Lin
Journal:  Clin Cardiol       Date:  2019-11-29       Impact factor: 2.882
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.